title: The use of Omegaven in treating parenteral nutrition-associated liver disease.
abstract: Parenteral nutrition (PN), containing fat emulsions derived from soybean, has been implicated in the progression of PN-associated liver disease and cholestasis, particularly in infants with short bowel syndrome. Clinical use of Omegaven, a parenteral fish-oil emulsion, has been shown in recent studies to be a promising therapy to reverse liver disease and cholestasis. This review summarizes the rationale, relevant clinical investigations and future direction of Omegaven therapy for PN-dependent infants.
authors: Department of Pediatric Gastroenterology, Stanford University Medical Center, Lucile Packard Children's Hospital, 750 Welch Road, Palo Alto, CA 94304, USA.
authors: K T
authors: KT
authors: Park
authors: C
authors: C
authors: Nespor
authors: J
authors: J
authors: Kerner
mesh_terms: D002779:Cholestasis / Q000209:etiology / Q000628:therapy; D005217:Fat Emulsions, Intravenous; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008107:Liver Diseases / Q000209:etiology* / Q000628:therapy*; D010288:Parenteral Nutrition / Q000009:adverse effects*; D012778:Short Bowel Syndrome / Q000628:therapy
chemical_list: D005217:Fat Emulsions, Intravenous; D015525:Fatty Acids, Omega-3